Health and Human Services Secretary Robert F. Kennedy, Jr. and Food and Drug Administration Commissioner Martin Makary announced the launch of a national study into the risks of the abortion pill mifepristone to women’s health.
Insurance claim data indicate that nearly 11 percent of women who used mifepristone from 2017 to 2023 experienced serious health complications within 45 days. The issues included hemorrhage, sepsis, cardiac problems, or anaphylaxis. The drug failed in almost 3 percent of cases, requiring surgical follow-up.
The FDA initially approved mifepristone for up to seven weeks of pregnancy, but it was extended to 10 weeks under President Obama’s administration in 2016. President Biden’s administration removed requirements for in-person dispensing and severe side effect reporting in 2023.
As the Lord Leads, Pray with Us…
- For Secretary Kennedy and Commissioner Makary as they conduct the survey into the health risks associated with the abortion pill.
- For HHS and FDA officials as they review the impact and side effects associated with widely used medications and prescription drugs.
- For the Lord to direct President Trump and members of his administration as they address issues facing the United States.
